Drug intelligence / Profile preview

AASTY-TLR

Development stage: Preclinical
Lead developer: Polyceutix
Modality: Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intratumoral

Overview

AASTY-TLR is a preclinical immunomodulatory copolymer developed by Polyceutix for the treatment of muscle-invasive bladder cancer (MIBC). Administered via intratumoral injection, the copolymer solubilizes tumor cell lipid bilayers and membrane proteins into polymer-lipid particles, also known as nanodiscs. This process releases cancer neoantigens in a solubilized form, facilitating their uptake by immune cells. The copolymer is conjugated with a Toll-like receptor (TLR) agonist that amplifies immune activation, triggering an adaptive anti-tumor response. The technology was developed as a spinout from the Technical University of Denmark (DTU).

Other names: MAASTY copolymerNanodiscs

Targets

TLR (Toll-like receptors)

Beyond the preview

Go deeper on AASTY-TLR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AASTY-TLR.

Explore the full profile